Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor

A molded article such as a tablet is provided for administration to an oral cavity of a subject to treat or prevent a cyclooxygenase-2 mediated condition, disorder or disease. The molded article comprises a moldable blend of a therapeutically effective amount of a selective cyclooxygenase-2 inhibito...

Full description

Saved in:
Bibliographic Details
Main Authors MARK J KONTNY, TUGRUL T KARARLI, TRANG T. LE
Format Patent
LanguageEnglish
Published 04.03.2002
Edition7
Subjects
Online AccessGet full text

Cover

Loading…
Abstract A molded article such as a tablet is provided for administration to an oral cavity of a subject to treat or prevent a cyclooxygenase-2 mediated condition, disorder or disease. The molded article comprises a moldable blend of a therapeutically effective amount of a selective cyclooxygenase-2 inhibitory drug with a pharmaceutically acceptable excipient carrier system consisting predominantly of one or more carbohydrates, wherein ingredients and amounts thereof in the molded article and a process for preparing the molded article are selected such that the molded article exhibits rapid disintegration in the oral cavity, and wherein the moldable blend is prepared by a process step not requiring wet granulation.
AbstractList A molded article such as a tablet is provided for administration to an oral cavity of a subject to treat or prevent a cyclooxygenase-2 mediated condition, disorder or disease. The molded article comprises a moldable blend of a therapeutically effective amount of a selective cyclooxygenase-2 inhibitory drug with a pharmaceutically acceptable excipient carrier system consisting predominantly of one or more carbohydrates, wherein ingredients and amounts thereof in the molded article and a process for preparing the molded article are selected such that the molded article exhibits rapid disintegration in the oral cavity, and wherein the moldable blend is prepared by a process step not requiring wet granulation.
Author MARK J KONTNY
TUGRUL T KARARLI
TRANG T. LE
Author_xml – fullname: MARK J KONTNY
– fullname: TUGRUL T KARARLI
– fullname: TRANG T. LE
BookMark eNqFyrsKAjEQQNEUWvj6BucHFjbKgu0iPmrRehmzs3EgzixJBPP3WthbXTjcuZmICs3M6YIj96FAz4klk4-YWTxoxACDxucrfEEFdAAEV1xQfRdPgomqDbA8-M5Z49JMBwyJVr8uzPp4uO7PFY3aURrRkVDu2tuuqa2tbbv9f3wA-Pg1Sw
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
Edition 7
ExternalDocumentID AU8501101A
GroupedDBID EVB
ID FETCH-epo_espacenet_AU8501101A3
IEDL.DBID EVB
IngestDate Fri Jul 19 13:00:12 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_AU8501101A3
Notes Application Number: AU19850001101
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20020304&DB=EPODOC&CC=AU&NR=8501101A
ParticipantIDs epo_espacenet_AU8501101A
PublicationCentury 2000
PublicationDate 20020304
PublicationDateYYYYMMDD 2002-03-04
PublicationDate_xml – month: 03
  year: 2002
  text: 20020304
  day: 04
PublicationDecade 2000
PublicationYear 2002
RelatedCompanies PHARMACIA CORPORATION
RelatedCompanies_xml – name: PHARMACIA CORPORATION
Score 2.5481021
Snippet A molded article such as a tablet is provided for administration to an oral cavity of a subject to treat or prevent a cyclooxygenase-2 mediated condition,...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Title Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20020304&DB=EPODOC&locale=&CC=AU&NR=8501101A
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV3dS8MwED_mFPVNp7L5mQfpW1H73YciWz8cwj4Ym-xtNF3KCqMta0X733sJrfqyt5BAuIT88rvL5e4AHo1YtUxUg_HwWpqsIaPIVLENWdWpEuuGZTBROmE0NoYL7X2pL1uwaWJhRJ7QL5EcEREVId5LcV_nf49YnvhbWTzRBLuy12DueFJjHSvc0yd5A8efTryJK7kuWpLSeOZYOie6l_4BHKISbXIs-B8DHpOS_yeU4AyOpjhXWp5Di6UdOHGbumsdOB7V7m5s1sgrLuBtFubJeluRdVI0KR6QdQgPsCdc8azLcJEsJiGJqmibZd8Vng5kKVkhSbpJKIJ3dwkPgT93hzJKtPpd_Kq_aERXr6CdZinrAqG2aVPdiNDYUbVnZtvMUjUk2ygOdTNS4h50981yvX_oBk5FrRP-w0q7hXa5-2R3SLklvRe79QMNfIXf
link.rule.ids 230,309,783,888,25576,76876
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV3dT8IwEL8gGvFNUQN-0Qezt0Xd9x6IgW2IygYhw_C2rGMLS8i2wIzy33ttmPrCW9MmzbXpr7-7Xu8O4F5LZENHNRgPr6GICjKKSCVTE2WVSomqGVrMSye4njacKW9zdV6DZRULw_OEfvHkiIioCPFe8vu6-HvEsvnfys0DTbErfx74XVuorGOJefoEu991JmN7bAmWhZak4E27hsqI7ql3AIeoYOsMC85Hn8WkFP8JZXAKRxOcKyvPoBZnTWhYVd21Jhy7O3c3NnfI25zDyzQs0sVqSxbppkrxgKxDWIA9YYrnrgwXyRMSkmgbrfL8e4unA1lKlEiaLVOK4F1fQGfg-NZQRImC38UHvVklunwJ9SzP4hYQauomVbUIjR1ZeYxNMzZkBck2SkJVj6SkDa19s1ztH-pAY-i7o2D06r1fwwmve8J-Wyk3UC_Xn_Et0m9J7_jO_QCAsojS
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Rapidly+disintegrating+oral+formulation+of+a+cyclooxygenase-2+inhibitor&rft.inventor=MARK+J+KONTNY&rft.inventor=TUGRUL+T+KARARLI&rft.inventor=TRANG+T.+LE&rft.date=2002-03-04&rft.externalDBID=A&rft.externalDocID=AU8501101A